Carl Zeiss Meditec AG share
Investing in Carl Zeiss Meditec AG is an investment in the future of the health sector. We drive the development of leading-edge technology and make it available for applications in the field of: ophthalmology, neurosurgery, ENT surgery, dental applications and systems for intraoperative radiotherapy.
Quotes, Charts & Orderbook
Security Identification Numbers
Stock exchange abbreviation |
AFX |
---|---|
ISIN |
DE0005313704 |
Reuters Identification Code (RIC) |
AFXG.F (exchange floor) |
Bloomberg |
AFX GR |
Key Facts at a Glance
-
ISIN
DE0005313704
Trading Segment
Prime Standard
Designated Sponsors
ODDO BHF Corporates & Markets AG
Paying Agent
Commerzbank AG
Share Capital
€89,440,570.00
Admitted Capital
€89,440,570.00
Category and Nominal Value
No-par value bearer shares at a nominal value of €1.00 per share
Stock Markets
Deutsche Börse in Frankfurt (XETRA and exchange floor, “Parkett”)
Regional stock exchanges in Berlin, Bremen, Düsseldorf, Hamburg, Munich and StuttgartCapital Measures
23-Mar-2017:
Increase of the share capital of €89,309,610.00
against cash contribution by €8,130,960.00 (approx. 10%) to
€89,440,570.00; subscription rights of shareholders were excluded.26-Oct-2006:
Increase of the share capital of €32,523,844.00 (divided into 32,523,844 no-par value shares) by €48,785,766.00 to €81,309,610.00 (divided into 81,309,610 no-par value shares); capital increase with subscription rights and against contributions in kind and cash contributions.10-May-2005:
Increase of the share capital of €29,682,182.00 against cash contribution by €2,841,662.00 (approx. 10%) to €32,523844.00; subscription rights of shareholders were excluded.01-Feb-2005:
Increase of the share capital of €28,416,628.00 against contribution in kind by €1,265,553.00
(4.45%) to €29,682,182.00; subscription rights of shareholders were excluded;
capital increase was part of the acquisition of the majority holding in IOLTech S.A.18-Sep-2003:
Increase of the share capital of €25,833,300.00 against cash contribution by €2,583,329.00
(10%) to €28,416,629.00; subscription rights of shareholders were excluded. -
-
2021/222020/212019/202018/192017/182016/17
XETRA
Year-end price (€1)
107.45
166.05
108.00
104.60
72.50
44.17
Year high (€1)
191.05
199.05
121.40
108.70
76.60
47.45
Year low (€1)
101.75
105.14
69.70
61.00
44.85
31.00
Year average (€)
141.67
142.65
98.18
81.80
56.91
39.70
Daily order book turnover (XETRA) in fiscal year
in €
15,367,421
14,817,336
16,090,137
13,264,306.00
4,988,993
3,430,556
Shares
109,627
105,938
167,107
162,154
85,818
86,412
Number of shares as of 30 September
(million shares)89.4
89.4
89.4
89.4
89.4
89.4
Market capitalization as of 30 September
(€m)9,610.40
14,851.60
9,659.6
9,355.5
6,484.4
3,950.1
Earnings per share (€)
3.29
2.64
1.37
1.79
1.41
1.57
Dividend per share (€)
1.10
0.90
0.5 3)
0.653)
0.552)
0.552)
Dividend yield (%)1)
1.0
0.5
0.5
0.6
1.24
1.62
-
Bank/Analyst
Current Rating
Date
Price Target
KeplerCheuvreux
Oliver ReinbergReduce
24-11-2023
85.00 €
ALPHAVALUE
Anas PatelBuy
23-11-2023
118.00 €
UBS
Graham DoyleNeutral
20-10-2023
87.00 €
Hauck & Aufhäuser
Alexander GalitsaBuy
12-10-2023
140.00 €
LBBW
Volker StollBuy
27-09-2023
112.00 €
Alster Research
Harald HofBuy
22-09-2023
100.00 €
HSBC
Sezgi OezenerBuy
05-09-2023
119.00 €
Bankhaus Metzler
Alexander NeubergerHold
16-08-2023
90.00 €
EQUI.TS GmbH
Thomas SchießleBuy
07-08-2023
115.00 €
Deutsche Bank AG
Falko FriedrichsHold
07-08-2023
100.00 €
ODDO BHF
Oliver MetzgerNeutral
04-08-2023
115.00 €
Berenberg Bank
Sam EnglandHold
04-08-2023
110.00 €
Bank of America Meryll Lynch
Julien OuaddourNeutral
10-05-2023
115.00 €
DZ Bank
Sven KürtenBuy
06-03-2023
155.00 €
Morningstar
Aaron Degagne09-08-2021
64.00 €
Nord/LB
Holger FechnerBuy
26-05-2021
172.00 €
Please note: Banks and securities firms use different terms for their equity ratings. The information contained in the table is based on publicly available sources that we consider reliable but for which we do not assume any liability.
In particular, we do not guarantee that the information is complete, accurate or up-to-date. All ratings are based on opinions given by the analysts in question. These do not necessarily reflect the opinion of Carl Zeiss Meditec AG. The assessments may change at any time without prior notice. Exemption from liability applies to Carl Zeiss Meditec AG; it does not refer to the correct rendering of the information based on external sources, in particular public sources.
Analyst assessments relating to Carl Zeiss Meditec AG shares are only revised each quarter and are therefore not continually updated.
-
ZEISS Shareholder Structure
Carl Zeiss Meditec AG's subscribed capital is composed of 89,440,570 ordinary shares, each with a theoretical par value of €1 per share. The ZEISS Group holds around 59% of the shares. According to our knowledge, the remaining 41% are in free float.
Download
-
1
As of the end of FY 30 September
-
2
Amount of dividend proposed by the Supervisory Board and the Management Board of Carl Zeiss Meditec AG.
-
3
Amount of dividend proposed by the Supervisory Board and the Management Board of Carl Zeiss Meditec AG.
-
4
Until FY 2016/17 ratio of dividend per share to opening price for the respective fiscal year, from FY 2017/18 ratio of dividend per share to closing rate on 30 September.